Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Andrea Cavazzoni(University of Parma), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi)
Cited by 45
Related Papers
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|606
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
|Journal of Clinical Oncology|2007|384
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|201
PTEN status in advanced colorectal cancer treated with cetuximab
|British Journal of Cancer|2009|85